The Trump administration signed an executive order imposing a 100% ad valorem duty on imported brand-name drugs, citing US “import reliance” and linking the policy to Section 232 national security authorities. The order includes a set of carveouts and reduced tariff rates tied to whether manufacturers commit to US manufacturing plans or hold “Most Favored Nation” agreements. Industry reaction was swift, with trade group PhRMA warning that tariff costs could jeopardize billions in US manufacturing and R&D investments. The framework also raises near-term operational questions for supply chains and pricing negotiations across drugmakers, especially those not already positioned to meet the order’s conditions. Separate reporting indicated additional tariff-related outreach is extending to smaller drugmakers, suggesting the administration is seeking confidential pricing and manufacturing agreements beyond the first wave of talks. For biotech firms, the immediate impact is likely to center on US launch economics, contract manufacturing leverage, and the ability to re-price or restructure commercial terms ahead of enforcement timelines.